Sumitomo’s Sunovion Unit Wins $18 Million in Mylan Patent Trial
Sumitomo Chemical Co. (4005)’s Sunovion Pharmaceuticals Inc. won an $18 million patent-infringement verdict in federal court in Delaware from Mylan Inc. (MYL) and its Dey Pharma unit over technology for asthma-treatment inhalers.
The jury decided today after a two-week trial that Dey induced and contributed to infringement of a series of patents for inhaler solutions, according to court electronic documents.
Jurors also ruled that the infringement was intentional, which may allow U.S. District Judge Leonard Stark to triple the damages.
“We firmly believe that the jury has erred and intend to seek reversal through post-trial motions and, if necessary, an appeal of the verdict and the damages award,” Mylan Chief Executive Officer Heather Bresch said in a statement.
Patricia Moriarty, a spokeswoman for Sunovion, didn’t immediately return a call for comment.
The case is Sunovion v. Dey and Mylan, 06CV113, U.S. District Court, District of Delaware (Wilmington).
To contact the editor responsible for this story: Michael Hytha at firstname.lastname@example.org